Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.

Barresi V, Eccher A, Simbolo M, Cappellini R, Ricciardi GK, Calabria F, Cancedda M, Mazzarotto R, Bonetti B, Pinna G, Sala F, Ghimenton C, Scarpa A.

Neuropathology. 2019 Nov 22. doi: 10.1111/neup.12608. [Epub ahead of print]

PMID:
31758617
2.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
3.

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.

Gondim DD, Gener MA, Curless KL, Cohen-Gadol AA, Hattab EM, Cheng L.

Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):722-725. doi: 10.1097/PAI.0000000000000702.

PMID:
30358614
4.

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Macaulay RJ.

Cancer Control. 2015 Apr;22(2):200-5. Review.

PMID:
26068765
5.

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.

Lee Y, Koh J, Kim SI, Won JK, Park CK, Choi SH, Park SH.

Acta Neuropathol Commun. 2017 Aug 29;5(1):62. doi: 10.1186/s40478-017-0465-1.

6.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

7.

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.

Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G, Brandes AA, de Biase D.

J Neurooncol. 2017 Nov;135(2):245-254. doi: 10.1007/s11060-017-2571-0. Epub 2017 Jul 26.

PMID:
28748342
8.

Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.

Chen YY, Ho HL, Lin SC, Hsu CY, Ho DM.

Neurosurgery. 2019 Sep 1;85(3):335-342. doi: 10.1093/neuros/nyy338.

PMID:
30113684
9.

[Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].

Liu QQ, Yin XX, Zou Y, Yu TP, Gong J, Chen XQ, Nie L, Xu M, Zhang MN, Zhou Q, Chen N.

Zhonghua Bing Li Xue Za Zhi. 2018 Sep 8;47(9):658-663. doi: 10.3760/cma.j.issn.0529-5807.2018.09.002. Chinese.

PMID:
30220117
10.

IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.

Robinson C, Kleinschmidt-DeMasters BK.

J Neuropathol Exp Neurol. 2017 Feb 1;76(2):151-154. doi: 10.1093/jnen/nlw112.

PMID:
28110298
11.

IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.

Chen N, Yu T, Gong J, Nie L, Chen X, Zhang M, Xu M, Tan J, Su Z, Zhong J, Zhou Q.

Pathology. 2016 Dec;48(7):675-683. doi: 10.1016/j.pathol.2016.07.010. Epub 2016 Oct 22.

PMID:
27780605
12.

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.

Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.

Klin Onkol. Fall 2017;30(5):361-371. doi: 10.14735/amko2017361.

PMID:
29031038
13.

Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.

Takei H, Shinoda J, Ikuta S, Maruyama T, Muragaki Y, Kawasaki T, Ikegame Y, Okada M, Ito T, Asano Y, Yokoyama K, Nakayama N, Yano H, Iwama T.

J Neurosurg. 2019 Aug 16:1-10. doi: 10.3171/2019.5.JNS19780. [Epub ahead of print]

PMID:
31419796
14.

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.

Wang LM, Li Z, Piao YS, Cai YN, Zhang LY, Ge HJ, Xu WW, Lu DH.

Chin Med J (Engl). 2019 Dec 20;132(24):2920-2926. doi: 10.1097/CM9.0000000000000565.

PMID:
31833906
15.

IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.

Kurian KM, Haynes HR, Crosby C, Hopkins K, Williams M.

Br J Neurosurg. 2013 Aug;27(4):442-5. doi: 10.3109/02688697.2013.771139. Epub 2013 Mar 1.

PMID:
23451940
16.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

17.

Biomarker-driven diagnosis of diffuse gliomas.

Appin CL, Brat DJ.

Mol Aspects Med. 2015 Nov;45:87-96. doi: 10.1016/j.mam.2015.05.002. Epub 2015 May 21. Review.

PMID:
26004297
18.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.

19.

IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.

Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhagan A, Thennarasu K, Chickabasaviah YT, Hegde AS, Chandramouli BA, Somasundaram K, Santosh V.

Am J Clin Pathol. 2012 Aug;138(2):177-84. doi: 10.1309/AJCPZOIY3WY4KIKE.

PMID:
22904127
20.

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P.

Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13.

Supplemental Content

Support Center